Seelos Therapeutics (SEEL) Financials

$0.25

$-0.92 (-78.63%)

As on 17-Dec-2024 09:30EDT

Market cap

$0 Mln

Revenue (TTM)

$2 Mln

P/E Ratio

0

P/B Ratio

15.1

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Operating Revenue	2.01	2.20	0.81	--	0.38	0.38
Cost of Revenue	0.06	0.06	0.05	--	--	22.56
Gross Profit	1.96	2.15	-0.05	--	--	-22.19
Operating Expenses	31.78	42.65	70.92	61.67	18.76	29.75
Operating Profit (EBIT)	-29.81	-40.50	-70.92	-61.67	-18.76	-29.75
Other Income	--	--	-2.60	--	-0.18	-21.48
Profit before Tax	4.09	-37.88	-73.53	-66.05	-19.10	-50.88
Provision for Tax	-0.04	-0.11	2.60	1.49	0.12	-0.50
Profit after Tax (Net Income)	4.09	-37.88	-76.14	-67.53	-19.22	-50.38
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	-73.53	-66.05	-19.10	-51.26

Liabilities ($ Mln)	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Shareholder's Funds	-28.13	-33.51	-10.61	57.32	2.57	-0.01
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	--	0.00	8.20	17.89	7.49	0.33
Current Liabilities	30.51	38.93	25.16	8.29	7.43	10.78
Total Liabilities	32.90	5.42	22.75	83.50	17.49	11.10

Assets ($ Mln)	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Non-Current Assets	0.05	0.02	0.07	0.04	--	--
Current Assets	2.33	5.40	22.67	83.46	17.49	11.10
Total Assets	32.90	5.42	22.75	83.50	17.49	11.10
Total Debt*	10.16	14.23	20.12	18.96	9.72	--
Net Current Assets	-28.18	-33.53	-2.48	75.17	10.07	0.32

Cashflow ($ Mln)	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Cash From Operating Activities	--	-23.91	-61.60	-49.00	-20.91	-19.31
Cash Flow from Investing Activities	--	--	--	--	--	--
Cash from Financing Activities	--	11.38	-1.60	112.07	26.31	29.52
Net Cash Inflow / Outflow	--	--	-63.20	--	5.40	10.22

Financials Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Adjusted EPS ($)	2.04	-3.87	-21.31	-19.20	-10.73	-55.91
Cash EPS ($)	--	-3.86	-21.30	-19.20	-10.73	-55.91
Adjusted Book Value ($)	--	--	--	16.30	1.44	--
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-2.44	-17.24	-13.93	-11.68	-21.42
Free Cash Flow per Share ($)	--	-2.44	-17.24	-13.93	-11.68	-21.42

Profitability Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
ROCE (%)	--	775.40	-177.49	-152.48	-312.80	-2,012.50
ROE (%)	--	171.72	-325.99	-225.50	-1,498.64	-3,928.50
ROA (%)	8.11	-269.01	-143.32	-133.74	-134.45	-678.28
EBIT Margin (%)	-1,480.73	-1,838.36	-9,135.15	--	-9,992.80	-7,932.53
Net Margin (%)	203.13	-1,719.56	4,239.31	--	-9,756.35	238.74
Cash Profit Margin (%)	0.00	--	--	--	--	--

Growth Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Revenue Growth (%)	76.05	1.73	--	-1.00	--	--
EBIT Growth (%)	46.24	45.13	39.99	-228.22	-25.97	-225.21
Net Profit Growth (%)	104.67	50.25	-12.74	-251.37	61.85	-445.15
EPS Growth (%)	108.98	0.82	-0.11	-0.79	0.81	0.38
Book Value Growth (%)	-4.24	--	--	--	--	--

Valuation Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Price / Earnings	0.00	-0.36	-0.03	-0.08	-0.15	-0.02
Price / Book Value	15.10	-0.41	-0.23	0.10	1.10	-172.52
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	2.35	-0.61	-0.10	0.88	0.17	0.31
Close Price ($)	9.55	22.24	325.92	782.40	758.40	643.20
High Price ($)	2,016.00	2,016.00	830.40	3,168.00	1,003.20	4,032.00
Low Price ($)	3.84	16.64	230.54	624.00	201.36	345.60
Market Cap ($ Cr)	0.21	--	--	--	--	--

Solvency Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Debt to Equity	--	-0.42	-1.90	0.33	3.78	--
Short term debt to equity ratio	-0.36	-0.42	-1.12	0.02	0.95	-137.57
Current Ratio	0.08	0.14	0.90	10.07	2.35	1.03
Quick Ratio	0.08	0.14	--	--	--	--
Interest Coverage	39.23	-539.99	-5,272.29	-76.97	-228.49	-1,025.76

Operating Efficiency Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Debtors to sales (%)	9.33	34.63	--	--	--	--
Asset Turnover	0.04	0.16	0.02	--	0.03	0.05
Receivable days	--	63.25	--	--	--	--
Inventory Days	--	0.01	--	--	--	--
Payable days	--	64,171.86	18,327.97	--	--	8.34
Cash Conversion Cycle	--	-64,108.60	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.